HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Helen Of Troy Buys Supplement Firm; L’Oreal Pore Poll; ICMAD Awards

This article was originally published in The Rose Sheet

Executive Summary

Helen of Troy’s $195 million acquisition of supplement firm Healthy Directions will increase its revenues by 10% annually, the firm says. More news in brief.

You may also be interested in...



Helen Of Troy Making Moves Across Brands To ‘Stabilize’ Personal Care

Firm launches new SKUs under its Pert Plus, Brut, Sure and Infusium23 brands as it seeks to stabilize its personal-care business, which has experienced declines for three consecutive quarters in fiscal 2015. Longer-term innovations and improvements in the firm’s struggling appliances segment should help return the division to growth, leadership suggests.

Parlux Serves Up Maria Sharapova Fragrance This Month

Maria Sharapova's premiere fragrance will roll out this month in seven Macy's East doors in the New York City area, according to Parlux

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019077

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel